Crossref indexed
Future Oncology
Published by Informa UK (Taylor & Francis).
ISSN 1479-6694 / 1744-8301
Submit to this journal
01
Aims & scope
Future Oncology publishes peer-reviewed research. Manuscripts pass a technical check and a scope check by the handling editor before going to independent reviewers.
02
Recently published
Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)
DOI 10.1080/14796694.2026.2749305 Yusuke Sano, Yuta Maruki, Chigusa Morizane, Shogo Nomura, Haruhiko Fukuda, Masafumi Ikeda, Masato Ozaka, Satoshi Kobayashi, Kazuyoshi Ohkawa, Nobumasa Mizuno, Hidetaka Tsumura, Nao Fujimori, Yoshito Komatsu, Noboru Takata, Ichiro Yasuda, Kohei Nakachi, Toru Otsuru, Takuya Honda, Takuji Okusaka, Makoto Ueno · 2026
Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)
DOI 10.1080/14796694.2026.2748246 Carolin Angendohr, Christian Weigel, Anselm Kunstein, Markus Joerdens, Thorsten Goetze, Salah-Eddin Al-Batran, Bianca Zäpf, Maria Gonzalez-Carmona, Cennet Sahin, Marie-Luise Berres, Friedrich Foerster, Najib Ben Khaled, Christine Koch, Arne Kandulski, Henning Wege, Jonel Trebicka, Leonie S. Jochheim, Michael T. Dill, Christoph Springfeld, Severin Daum, Christoph Treese, Ursula Ehmer, Tom Luedde, Johannes Bode, Christoph Roderburg · 2026
Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis
DOI 10.1080/14796694.2026.2750718 Siyuan Cui, Kui Zhao, Na Wang, Yuan Meng, Xiaoshan Wang, Chaoran Wang, Fanming Kong · 2026
AI-driven analysis of genomic alterations in colorectal cancer patients
DOI 10.1080/14796694.2026.2751396 Enrique Velazquez-Villarreal · 2026
First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis
DOI 10.1080/14796694.2026.2750655 Guojin Zhou, Jie Chen, Liuxian Guo, Jing Xu · 2026
Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis
DOI 10.1080/14796694.2026.2748258 Yuliya V. Perfilyeva, Nurshat Abdolla, Aikyn Kali, Raikhan Tleulieva, Anastassiya V. Perfilyeva, Yuriy A. Skiba, Yekaterina O. Ostapchuk · 2026
Evaluating taletrectinib in the treatment of patients with
<i>ROS1</i>
fusion-positive non–small cell lung cancer
DOI 10.1080/14796694.2026.2740954 Misako Nagasaka, Cathleen J. Park, Zhaohui L. Arter, Torrance Teng, Jacob Lee, Rozhan Ziari, Ravand Samaeekia, Sai-Hong Ignatius Ou · 2026
Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?
DOI 10.1080/14796694.2026.2746184 Aslı Geçgel, Salih Tünbekici · 2026
Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma
DOI 10.1080/14796694.2026.2739185 Dina I. Hemdan, Salwa Sabet, Lobna Ezz El-Arab, Mohamed Alorabi, Haidan M. El-Shorbagy, Nashwa El-Khazragy · 2026
Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
DOI 10.1080/14796694.2026.2742759 Letizia Matera, Julian David Etessami, Carmine Valenza, Giuseppe Curigliano · 2026
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology
DOI 10.1080/14796694.2026.2742677 Martina Izzi, Kristian Shtembari, Stefano Specchiarello, Chiara Calandrelli, Silvia Mancini, Marinella Micol Mela, Virginia Rossi, Roberta Giorgione, Daniele Rossini, Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello · 2026
DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma
DOI 10.1080/14796694.2026.2739789 Fan Yang, Weikang Tao, Zihang Zhong, Jia Fan, Hao Yu, Shukui Qin · 2026
Journal metrics
Total DOIs5,676
Current DOIs863
Backfile DOIs4,813
Published here0
Publish with us
Five steps, about 15 minutes. You can save and come back at any point.
Submit manuscript